These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 32770851

  • 1. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Iborra M, Beltrán B, Fernández-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, Gutiérrez A, Sierra-Ausin M, Mesonero F, Ferreiro-Iglesias R, Hinojosa J, Calvet X, Sicilia B, González-Muñoza C, Antolín B, González-Vivo M, Carbajo AY, García-López S, Martín-Cardona A, Surís G, Martin-Arranz MD, de Francisco R, Cañete F, Domènech E, Nos P, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa).
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1017-1030. PubMed ID: 32770851
    [Abstract] [Full Text] [Related]

  • 2. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
    Iborra M, Beltrán B, Fernández-Clotet A, Gutiérrez A, Antolín B, Huguet JM, De Francisco R, Merino O, Carpio D, García-López S, Mesonero F, Navarro P, Ferreiro-Iglesias R, Carbajo AY, Rivero M, Gisbert JP, Piñero-Pérez MC, Monfort D, Bujanda L, García-Sepulcre MF, Martín-Cardona A, Cañete F, Taxonera C, Domènech E, Nos P, GETECCU Group (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa).
    Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
    [Abstract] [Full Text] [Related]

  • 3. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernolle G, Van Assche G, Gils A, Vermeire S, Ferrante M.
    J Crohns Colitis; 2019 Jul 25; 13(7):864-872. PubMed ID: 30715258
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Ollech JE, Normatov I, Peleg N, Wang J, Patel SA, Rai V, Yi Y, Singer J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J.
    Clin Gastroenterol Hepatol; 2021 Jan 25; 19(1):104-110. PubMed ID: 32109634
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M.
    Scand J Gastroenterol; 2012 May 25; 47(5):528-37. PubMed ID: 22356594
    [Abstract] [Full Text] [Related]

  • 8. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, Löwenberg M, Dijkstra G, Oldenburg B, de Boer NKH, van der Marel S, Bodelier AGL, Jansen JM, Haans JJL, Theeuwen R, de Jong D, Pierik MJ, Hoentjen F.
    J Crohns Colitis; 2020 Jan 01; 14(1):33-45. PubMed ID: 31219157
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, De Vos M, Van Moerkercke W, Rahier JF, Bossuyt P, Dutré J, Humblet E, Staessen D, Peeters H, Van Hootegem P, Louis E, Franchimont D, Baert F, Vermeire S, Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group].
    J Crohns Colitis; 2019 Oct 28; 13(11):1401-1409. PubMed ID: 30989232
    [Abstract] [Full Text] [Related]

  • 14. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A, Al Lehaibi LH, Alomar M, Aldhuwayan F, Alshouish S, Al-Ali AY, Almudhry Z, Almulhim A, Althagafi A, Aldosari S, AlAmeel T.
    Saudi J Gastroenterol; 2024 Sep 01; 30(5):324-334. PubMed ID: 39157885
    [Abstract] [Full Text] [Related]

  • 15. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R.
    Inflamm Bowel Dis; 2017 May 01; 23(5):833-839. PubMed ID: 28328624
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.
    Clin Gastroenterol Hepatol; 2017 Sep 01; 15(9):1427-1434.e2. PubMed ID: 28365485
    [Abstract] [Full Text] [Related]

  • 19. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Hanžel J, Koželj M, Špes Hlastec A, Kurent T, Sever N, Zdovc J, Smrekar N, Novak G, Štabuc B, Grabnar I, Drobne D.
    Eur J Gastroenterol Hepatol; 2021 Dec 01; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.